Skip to main content
. Author manuscript; available in PMC: 2017 Sep 20.
Published in final edited form as: Immunity. 2016 Aug 11;45(3):513–526. doi: 10.1016/j.immuni.2016.07.016

Figure 3. Casp8−/−Mlkl−/− mice develop progressive severe lymphadenopathy.

Figure 3

(A) Cross section of immune cells in bone marrow, spleen and lymph nodes from mice of the indicated genotypes at 20 days and 70 days of age (n = 3). Different cell subsets were determined by flow cyotmetry using the following markers: B cells (B220+ or CD19+), T cells (CD3+), Monocytes and Macrophages (MAC-1+), Granulocytes (GR-1+), Erythroid cells (TER119+) and NK cells (NK1.1+ and NKp46+). Data represent mean ± SD (n = 3). (B and C) Weight and total cell numbers of the lymph nodes (axillary, brachial, inguinal and mesenteric) and spleen from mice of the indicated genotypes at, (A) 50 days, and (B) 100 days. *P<0.05, ***P<0.0001 compared to WT mice; #P<0.05, ##P<0.01, ###P<0.0001 compared to Casp8−/−Ripk3−/− mice.

(D) Kaplan-Meyer survival curves for WT (n = 15), Mlkl−/− (n = 19), Casp8+/−Mlkl−/− (n = 39), Casp8−/−Mlkl−/− (n = 22) and Casp8−/−Ripk3−/− (n = 31) mice.

(E) Kaplan-Meyer survival curves for control (MLKL) (n=32, FaddwtMlkl−/− or Fadd+/−Mlkl−/−), Fadd−/−Mlkl−/− (n = 34), control (RIP3) (n=44, FaddwtRipk3−/− or Fadd+/−Ripk3−/−), and Fadd−/− Ripk3−/− (n = 28) mice. Survival of mice of different genotypes was compared by log-rank test. **P<0.001, ***P<0.0001.

See also Figure S3.